University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer

Simple item page
dc.contributor.authorWalker, Alexandra K.
dc.contributor.authorKaraszi, Katalin
dc.contributor.authorValentine, Helen
dc.contributor.authorStrauss, Victoria Y.
dc.contributor.authorChoudhury, Ananya
dc.contributor.authorMcGill, Shaun
dc.contributor.authorWen, Kaisheng
dc.contributor.authorBrown, Michael D.
dc.contributor.authorRamani, Vijay
dc.contributor.authorBhattarai, Selina
dc.contributor.authorTeo, Mark T.W.
dc.contributor.authorYang, Lingjian
dc.contributor.authorMyers, Kevin A.
dc.contributor.authorDeshmukh, Nayneeta
dc.contributor.authorDenley, Helen
dc.contributor.authorBrowning, Lisa
dc.contributor.authorLove, Sharon B.
dc.contributor.authorIyer, Gopa
dc.contributor.authorClarke, Noel W.
dc.contributor.authorHall, Emma
dc.contributor.authorHuddart, Robert
dc.contributor.authorJames, Nicholas D.
dc.contributor.authorHoskin, Peter J.
dc.contributor.authorWest, Catharine M.L.
dc.contributor.authorKiltie, Anne E.
dc.contributor.institutionUniversity of Aberdeen.Rowett Instituteen
dc.date.accessioned2024-04-16T15:30:01Z
dc.date.available2024-04-16T15:30:01Z
dc.date.issued2019-07-15
dc.descriptionFunding Information: Disclosures: S.B., L.B., A.C., E.H., R.H., N.J., A.E.K., V.S., and C.W. report grant funding from Cancer Research UK during the conduct of the study. A.C. is a Senior Editor of IJROBP and reports nonfinancial support from ASCO and ESTRO; personal fees and nonfinancial support from Bayer PLC; grants from Prostate Cancer UK, Medical Research Council UK, and National Institute for Health Research UK; grants, personal fees, and nonfinancial support from Elekta AB; and personal fees from ASTRO, outside the submitted work. E.H. reports grants from Merck Sharp & Dohm, grants and nonfinancial support from AstraZeneca, grants from Janssen-Cilag, grants and nonfinancial support from Bayer, grants from Aventis Pharma Limited (Sanofi), and grants from Accuray Inc., outside the submitted work. R.H. reports grants and personal fees from MSD and Roche; personal fees from Bristol Myers Squibb and Janssen; and grants from Elekta, outside the submitted work. G.I. reports personal fees from Bayer Pharmaceuticals, outside the submitted work.This work was funded by CRUK Biomarkers and Imaging Discovery and Development grant (C15140/A13492). The BC2001 trial was supported by grants (C547/A2606, C547/A6845, C9764/A9904, and C1491/A9895) from Cancer Research UK. The work was also supported by CRUK grant C2094/A11365, CRUK grant C5529/A16895, CRUK grant C5255/A15935, an MRC studentship MR/K501256/1, CRUK funding to the Cancer Research Manchester Centre (C147/A18083, C147/A25254), the NIHR Manchester, NIHR Oxford (Molecular Diagnostics Theme/Multimodal Pathology Theme), and Royal Marsden/Institute of Cancer Research Biomedical Research Centres. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. Disclosures: S.B., L.B., A.C., E.H., R.H., N.J., A.E.K., V.S., and C.W. report grant funding from Cancer Research UK during the conduct of the study. A.C. is a Senior Editor of IJROBP and reports nonfinancial support from ASCO and ESTRO; personal fees and nonfinancial support from Bayer PLC; grants from Prostate Cancer UK, Medical Research Council UK, and National Institute for Health Research UK; grants, personal fees, and nonfinancial support from Elekta AB; and personal fees from ASTRO, outside the submitted work. E.H. reports grants from Merck Sharp & Dohm, grants and nonfinancial support from AstraZeneca, grants from Janssen-Cilag, grants and nonfinancial support from Bayer, grants from Aventis Pharma Limited (Sanofi), and grants from Accuray Inc., outside the submitted work. R.H. reports grants and personal fees from MSD and Roche; personal fees from Bristol Myers Squibb and Janssen; and grants from Elekta, outside the submitted work. G.I. reports personal fees from Bayer Pharmaceuticals, outside the submitted work. This work was funded by CRUK Biomarkers and Imaging Discovery and Development grant ( C15140/A13492). The BC2001 trial was supported by grants (C547/A2606, C547/A6845, C9764/A9904, and C1491/A9895) from Cancer Research UK. The work was also supported by CRUK grant C2094/A11365, CRUK grant C5529/A16895, CRUK grant C5255/A15935, an MRC studentship MR/K501256/1, CRUK funding to the Cancer Research Manchester Centre ( C147/A18083, C147/A25254), the NIHR Manchester, NIHR Oxford (Molecular Diagnostics Theme/Multimodal Pathology Theme), and Royal Marsden/ Institute of Cancer Research Biomedical Research Centres. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. Publisher Copyright: © 2019 The Authorsen
dc.description.statusPeer revieweden
dc.format.extent10
dc.format.extent1477340
dc.identifier195023287
dc.identifier4f664d96-b11b-4987-aabb-91b7f1c9f89d
dc.identifier85065812956
dc.identifier30885775
dc.identifier.citationWalker, A K, Karaszi, K, Valentine, H, Strauss, V Y, Choudhury, A, McGill, S, Wen, K, Brown, M D, Ramani, V, Bhattarai, S, Teo, M T W, Yang, L, Myers, K A, Deshmukh, N, Denley, H, Browning, L, Love, S B, Iyer, G, Clarke, N W, Hall, E, Huddart, R, James, N D, Hoskin, P J, West, C M L & Kiltie, A E 2019, 'MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer', International Journal of Radiation Oncology Biology Physics, vol. 104, no. 4, pp. 809-818. https://doi.org/10.1016/j.ijrobp.2019.03.015en
dc.identifier.doi10.1016/j.ijrobp.2019.03.015
dc.identifier.iss4en
dc.identifier.issn0360-3016
dc.identifier.otherORCID: /0000-0001-7208-2912/work/114166764
dc.identifier.urihttps://hdl.handle.net/2164/23267
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85065812956&partnerID=8YFLogxKen
dc.identifier.vol104en
dc.language.isoeng
dc.relation.ispartofInternational Journal of Radiation Oncology Biology Physicsen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectR Medicineen
dc.subjectRadiationen
dc.subjectOncologyen
dc.subjectRadiology Nuclear Medicine and imagingen
dc.subjectCancer Researchen
dc.subjectCancer Research UKen
dc.subjectC15140/A13492en
dc.subjectC547/A2606en
dc.subjectC547/A6845en
dc.subjectC9764/A9904en
dc.subjectC1491/A9895en
dc.subjectC5255/A15935en
dc.subjectC147/A18083en
dc.subjectC147/A25254en
dc.subjectC2094/A11365en
dc.subjectC5529/A16895en
dc.subjectMedical Research Council (MRC)en
dc.subjectMR/K501256/1en
dc.subjectSupplementary Informationen
dc.subjectSupplementary material for this article can be found at https://doi.org/ 10.1016/j.ijrobp.2019.03.015en
dc.subject.lccRen
dc.titleMRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Canceren
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Walker_etal_IJROBP_MRE11_Predictive_Biomarker_VOR.pdf
Size:
1.41 MB
Format:
Adobe Portable Document Format
Download

Collections

All research

The Sir Duncan Rice Library

University of Aberdeen

Bedford Road

Aberdeen

AB24 3AA


Tel: +44 (0)1224 273330

Email: library@abdn.ac.uk

Share and keep up to date


FacebookTwitterWordpress